Featured Content

H. Jack West, MD
Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)

Analysis Finds Select Group of Stage IV Lung Cancer Patient Population Achieves Long-term Survival After Aggressive Treatments

(ASTRO) Sept 16, 2014 - A large, international analysis of patients with stage IV non-small cell lung cancer (NSCLC) indicates that a patient’s overall survival (OS) rate can be related to factors including the timing of when metastases develop and lymph node involvement, and that aggressive treatment for “low-risk” patients leads to a five-year OS rate of 47.8 percent, according to research presented today at ASTRO.

Commentary: Dr. Ashworth appropriately cautions that the finding that a minority of patients with stage IV NSCLC and who had...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

(Yahoo! Finance) Sept 19, 2014 - Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).
read article »

The Transformation

(The New Yorker) Sept 15, 2014 - Is it possible to control cancer without killing it?
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Analysis Finds Select Group of Stage IV Lung Cancer Patient Population Achieves Long-term Survival After Aggressive Treatments (ASTRO)

Dr. Ashworth appropriately cautions that the finding that a minority of patients with stage IV NSCLC and who had...posted by: H. Jack West, MD

Chest Radiation Ups Survival in Small-Cell Lung Cancer (Medscape Medical News)

This isn't going to apply for every patient, and probably not even the majority of patients with extensive stage...posted by: H. Jack West, MD

Medicare Bundled Payments Initiative and Oncology Care (JD Supra/Foley & Lardner LLP)

So the trend continues as we explore new alternate compensation models. We have heard about bundling for a long...posted by: Thomas Marsland, MD

Long-term Androgen Deprivation (LTAD) Therapy Combined with High-dose Radiation Therapy (HDRT) for Prostate Cancer Improves Biochemical Control and Survival Rates (ASTRO)

These results are similar to previously reported data. Other studies show that unless there is a program to maintain...posted by: STANLEY BROSMAN

Actionable Genome Consortium Forms with Cross Disciplinary Leaders from World-Renowned Cancer Institutions (Yahoo! Finance)

The demonstration of clinical utility, as it applies to NGS testing, is the main topic of discussion among payers....posted by: Winston, Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


Bayer Biopharmaceuticals, Inc. has posted 20 new jobs.


Ipsen Biopharmaceuticals, Inc. has posted over 50 new jobs.


Novocure has posted 4 jobs.


View OBR Job Board>>


KH_OMA_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
IMUC +8.62%
CYTK +7.25%
AVEO +6.72%
NYMX -12.63%
XNCR -7.36%
RNN -6.99%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: Q3 2014
Company: ERYTECH Pharma
Product: ERY-ASP/GRASPA®

Date: Q3 or Q4 2014
Company: Sunesis Pharmaceuticals
Product: vosaroxin (trademark name Qinprezo™)

Date: October 16, 2014
Company: Navidea Biopharmaceuticals
Product: Lymphoseek® (technetium Tc 99m tilmanocept) Injection

See All OBR Radar items»